Creatine Supplementation in Type 2 Diabetic Patients: A Systematic Review of Randomized Clinical Trials
Mancini de Sousa M, Nakata MTK, Baldini CES, de Oliveira-Sales EB, Boim MA, Martimbianco ALC, Maquigussa E
Current diabetes reviews · 4 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2021-08-15 · Curr Diabetes Rev · vol. 18 · número 3 · pág. e120721194709
- Editorial
- Bentham Science Publishers
- Citado
- 4 citas · más que el 26% de estudios similares · 0.1× el promedio de su campo
- Referencias
- 29 trabajos
- Acceso
- De pago
- Áreas de investigación
- Diabetes Treatment and Management · Diabetes Management and Research · Muscle metabolism and nutrition
- Palabras clave
- creatine supplementation, type 2 diabetes, glycemic control, HbA1c, metformin, glibenclamide, antidiabetic drugs, blood glucose reduction, adverse effects
- MeSH
- humans, diabetes mellitus, type 2, metformin, creatine, glyburide, blood glucose, hypoglycemic agents, dietary supplements, randomized controlled trials as topic
7 autores
- Ana Luiza Cabrera Martimbianco🇧🇷 · autor de correspondenciaUniversidade Metropolitana de Santos
- Marcella Mancini de Sousa🇧🇷Universidade Metropolitana de Santos
- M Nakata🇧🇷Universidade Metropolitana de Santos
- Carlos Eduardo Slateff Baldini🇧🇷Universidade Metropolitana de Santos
- Elizabeth Barbosa Oliveira‐Sales🇧🇷Universidade Metropolitana de Santos
- Mírian Aparecida Boim🇧🇷Universidade Metropolitana de Santos; Universidade Federal de São Paulo
- Edgar Maquigussa🇧🇷Universidade Metropolitana de Santos; Universidade Federal de São Paulo
Resumen
El texto original del estudio, en el idioma en que se publicó.
Type 2 Diabetes Mellitus (DM) is the most common form of diabetes. The initial treatment of type 2 DM consists of the adoption of healthy lifestyle habits together with several classes of hypoglycemic agents. However, these medications are not always able to reduce the blood glucose levels in all patients. Therefore, creatine supplementation has emerged as a new putative candidate for type 2 DM treatment. This systematic review aimed to investigate the effects (benefits and harms) of creatine supplementation in patients with type 2 diabetes through a systematic review. The studies were searched in MEDLINE, EMBASE, LILACS, CENTRAL, SPORTDiscus, and CINAHL databases, without date or language restrictions. Methodological quality was assessed using the Cochrane risk-of-bias table. The certainty of the evidence was classified using the Grading of Recommendations Assessment, Development and Evaluation approach. Three randomized controlled trials (RCTs) were included (87 participants). Overall, the methodological quality was classified as unclear to a high risk of bias. Each trial compared creatine supplementation with a different control group (placebo, metformin, and glibenclamide). Creatine supplementation seems to be effective in decreasing glycemic levels and glycosylated hemoglobin concentrations compared to placebo. No difference was observed compared to metformin or glibenclamide with creatine, and all treatments were able to reduce blood glucose levels. No major adverse effects were observed. Based on the low certainty of evidence, creatine supplementation was shown to be a hypoglycemic intervention for patients with type 2 diabetes, without major adverse events reported. However, well- designed RCTs with larger sample sizes and long-term outcomes are needed to support this evidence.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.